



## **Shionogi Announces Appointment of Corporate officers, the Establishment of new Organization and Personnel Reassignment (Effective April 1, Jun 18, and July 1, 2025)**

OSAKA, Japan, March 24, 2025 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "SHIONOGI") announces that the appointment of corporate officers will take effect on April 1, 2025. And it will implement the following new establishment of new organization and personnel reassignment, effective June 18 and July 1. 2025.

### 1. Appointment of Corporate Officers (Effective; April 1,2025)

Name	New Position	Present Position
Toshiyuki Asaki	Corporate Officer, Senior Vice President, Drug Discovery Research Division	President, Shionogi Techno Advance Research Co., Ltd.
Masako Kudo	Corporate Officer, Senior Vice President, Corporate Strategy Division	Vice President, Finance & Accounting Department
Kenji Matsuo	Corporate Officer, Vice President, Internal Control Department	Vice President, Internal Control Department

### 2. Establishment of new Organization (Effective; Jun 18, 2025)

- In conjunction with the transition to a company with an Audit and Supervisory Committee, a new "Audit and Supervisory Committee Office" will be established directly under the Audit and Supervisory Committee.

### 3. Personnel Reassignments (Effective; Jun 18, 2025)

Name	New Position	Present Position
Kyoko Nagao	Vice President, Audit and Supervisory Committee Office	Internal Control Department

#### 4. Personnel Reassignments (Effective; July 1, 2025)

Name	New Position	Present Position
<b>R&amp;D Supervisory Unit</b>		
John Keller	Senior Executive Officer, Senior Vice President, R&D Supervisory Unit	Senior Executive Officer, Senior Vice President, R&D Supervisory Unit and Pharmaceutical Technology Research Division
<b>Pharmaceutical Technology Research Division</b>		
Tatsumori Yoshida	Corporate Officer, Senior Vice President, Pharmaceutical Technology Research Division	Corporate Officer, Chairman and CEO of Ping An Shionogi Company Ltd. and Shionogi (Hong Kong) Commerce Ltd.
<b>Healthcare Business Supervisory Unit</b>		
<b>[Ping An Shionogi Company Ltd.]</b>		
Hirofumi Nagatome	Chairman and CEO	Healthcare Business Supervisory Unit Office
<b>[Shionogi (Hong Kong) Commerce Ltd.]</b>		
Hirofumi Nagatome	Chairman and CEO	Healthcare Business Supervisory Unit Office

#### Forward-Looking Statements

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

#### For Further Information, Contact:

SHIONOGI Website Inquiry Form:

<https://www.shionogi.com/global/en/contact.html>

SHIONOGI Divisions (June 18, 2025)

